Sequana Medical appoints leading experts as Heart Failure Scientific Advisors

News
- 19/09/2019

Dr Butler, Dr Costanzo, Dr Tang and Dr Testani to advise on alfapump® DSR development

Ghent, Belgium: 19 September 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), innovators in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces the appointments of Dr Javed Butler, Dr Maria Rosa Costanzo, Dr Wilson Tang and Dr Jeffrey Testani as the Company’s Heart Failure Scientific Advisors.

The Sequana Medical management team will work closely with the Scientific Advisors on the development of alfapump DSR (Direct Sodium Removal). Built on its proven alfapump platform, alfapump DSR is Sequana Medical’s breakthrough approach for the management of fluid overload in patients suffering from heart failure. Positive data from the first-in-human single dose DSR proof-of-concept study were presented at the Heart Failure 2019 congress in May 2019 and a first-in-human alfapump DSR study is planned to commence later this year, with results expected in the first half of 2020.

More info on Sequana Medical‘s website.